Regeneron Pharmaceuticals, Inc. (LON:0R2M)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 55.32B |
| Revenue (ttm) | 10.60B |
| Net Income (ttm) | 3.41B |
| Shares Out | n/a |
| EPS (ttm) | 30.94 |
| PE Ratio | 16.24 |
| Forward PE | 15.64 |
| Dividend | 2.68 (0.37%) |
| Ex-Dividend Date | Nov 20, 2025 |
| Volume | 418 |
| Average Volume | 1,647 |
| Open | 722.36 |
| Previous Close | 723.30 |
| Day's Range | 717.60 - 735.58 |
| 52-Week Range | 477.01 - 812.89 |
| Beta | n/a |
| RSI | 56.06 |
| Earnings Date | Feb 3, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial numbers in USD Financial StatementsNews
Regeneron Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript
Regeneron Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript
Canaccord Genuity Raises Price Target for Regeneron Pharmaceuticals (REGN) to $1,057 | REGN ...
Canaccord Genuity Raises Price Target for Regeneron Pharmaceuticals (REGN) to $1,057 | REGN Stock News
Market Whales and Their Recent Bets on REGN Options
Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ: REGN) revealed 12 unusual trades. Delving in...
REGN: BMO Capital Raises Price Target and Maintains Outperform Rating | REGN Stock News
REGN: BMO Capital Raises Price Target and Maintains Outperform Rating | REGN Stock News
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Morgan Stanley Downgrades Regeneron (REGN) Citing Fair Valuation
Morgan Stanley Downgrades Regeneron (REGN) Citing Fair Valuation
Regeneron downgraded at Morgan Stanley on valuation level
Morgan Stanley downgrades Regeneron (REGN), citing fair valuation. Read more here.
REGN: Morgan Stanley Downgrades Regeneron Pharmaceuticals Rating to Equal-Weight | REGN Stock News
REGN: Morgan Stanley Downgrades Regeneron Pharmaceuticals Rating to Equal-Weight | REGN Stock News
Regeneron Pharmaceuticals Inc at Evercore ISI Healthcare Conference Transcript
Regeneron Pharmaceuticals Inc at Evercore ISI Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Evercore 8th Annual Healthcare Conference Transcript
Regeneron Pharmaceuticals, Inc. (REGN) Evercore 8th Annual Healthcare Conference December 2, 2025 1:20 PM ESTCompany ParticipantsRyan Crowe - Senior Vice...
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.
Nasdaq 100 Movers: REGN, APP
In early trading on Tuesday, shares of Applovin topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.4%. Year to date, Applovin registers a 104.8% gain. And th...
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Regeneron Pharmaceuticals (NASDAQ: REGN) has outperformed the market over the past 15 years by 11.76% on an annualized basis producing an average annual return of 23.85%. Currently, Regeneron Pharmac...
Regeneron (REGN) Invests $150M in Tessera's Gene Editing Therapy
Regeneron (REGN) Invests $150M in Tessera's Gene Editing Therapy
Regeneron inks deal with Tessera to develop gene editing therapy
Regeneron Invests $150 Million In Tessera To Advance One-Time Gene Therapy For Rare Genetic Disorder
Regeneron and Tessera partner on TSRA-196, a ... Full story available on Benzinga.com
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
Regeneron (REGN) Partners with Tessera to Advance Gene Therapy for AATD
Regeneron (REGN) Partners with Tessera to Advance Gene Therapy for AATD
Regeneron, Tessera Enter Collaboration To Develop TSRA-196
(RTTNews) - Regeneron Pharmaceuticals (REGN) and Tessera Therapeutics announced a collaboration to develop and commercialize TSRA-196, Tessera's lead investigational in vivo Gene Writing program for t...
Regeneron and Tessera Therapeutics to Jointly Develop TSRA-196, an Investigational Gene Editing Therapy for Alpha-1 Antitrypsin Deficiency (AATD)
TARRYTOWN, N.Y. and SOMERVILLE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., today announced a global collaboration to develop...
Should You Buy This Biotech Stock That Just Gained 5% in 1 Day?
Sales of Regeneron Pharmaceuticals' Eylea have declined over the past few quarters due to competition. However, the company launched a new formulation of the medicine that just earned another label ex...
SNY & REGN's Dupixent Gets EU Nod for Chronic Spontaneous Urticaria
Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.
EU approves Sanofi and Regeneron’s Dupixent as first targeted therapy for chronic spontaneous urticaria in a decade
Please provide the article or its content so I can generate the meta description as per your instructions.
Sanofi And Regeneron : European Commission Approves Dupixent For CSU In Adults And Adolescents
(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) and Regeneron Pharmaceuticals Inc. (REGN) announced that the European Commission has approved Dupixent (dupilumab) as a first-line targeted treatment for modera...
Press Release: Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly re...